FDA Device Center Touts Clinical Trial Review Performance
This article was originally published in The Gray Sheet
Executive Summary
According to the latest numbers, CDRH says it has reduced median investigational review exemption review times to 30 days, and three out of four IDEs are now fully approved after two review cycles.
You may also be interested in...
CDRH Touts Progress On Clinical Study Reviews
The device center says that the number of review cycles and the median review time for investigational device exemptions dropped ahead of expectations during the past year. Aggressive goals remain for 2015.
FDA Finalizes Guidance On Early-Stage Clinical Trials
FDA released final guidance on granting investigational device exemptions for early feasibility medical device clinical studies Oct. 1. It grants manufacturers additional flexibility to change the clinical protocol in early feasibility trials, which are often conducted as the device’s design is still being finalized.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”